Standout Papers
Citation Impact
Citing Papers
Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer
2019
Crippling life support for SARS-CoV-2 and other viruses through synthetic lethality
2020 StandoutNobel
PARP inhibitors: Synthetic lethality in the clinic
2017 StandoutScience
Reactive oxygen species, toxicity, oxidative stress, and antioxidants: chronic diseases and aging
2023 Standout
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
2017 Standout
Secure, privacy-preserving and federated machine learning in medical imaging
2020 Standout
Cancer immunotherapies targeting the PD-1 signaling pathway
2017 StandoutNobel
Breast cancer
2019 Standout
Triple-negative breast cancer molecular subtyping and treatment progress
2020 Standout
HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across species
2019 StandoutNobel
Clinical implications of molecular heterogeneity in triple negative breast cancer
2015
Cancer treatment and survivorship statistics, 2022
2022 Standout
Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation
2018
Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy
2015
Trabectedin for the treatment of breast cancer
2015
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial
2016
Pancreatic cancer
2020 Standout
PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions
2016
The biology and management of non-small cell lung cancer
2018 StandoutNature
Genetic epidemiology of ovarian cancer and prospects for polygenic risk prediction
2017
Olaparib: First Global Approval
2015
PD-1/PD-L1 and immunotherapy for pancreatic cancer
2017
Precision Diagnosis and Treatment for Advanced Non–Small-Cell Lung Cancer
2017
Pancreatic cancer
2016 Standout
Triple-negative breast cancer: treatment challenges and solutions
2016
Understanding and targeting resistance mechanisms in NSCLC
2017
Hepatocellular carcinoma
2021 Standout
ESMO-Magnitude of Clinical Benefit Scale version 1.1
2017
RAS-targeted therapies: is the undruggable drugged?
2020
A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments
2017
Cancer-associated cachexia
2018 Standout
A machine learning algorithm predicts molecular subtypes in pancreatic ductal adenocarcinoma with differential response to gemcitabine-based versus FOLFIRINOX chemotherapy
2019
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
Therapeutic strategies to target RAS-mutant cancers
2018
Targeting apoptosis in cancer therapy
2020 Standout
Implementing Genome-Driven Oncology
2017
Drug development in the era of precision medicine
2017
Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy
2015
New therapeutic strategies to treat human cancers expressing mutant p53 proteins
2018
Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer
2016
Broadening horizons: the role of ferroptosis in cancer
2021 Standout
Regulation and Function of the PD-L1 Checkpoint
2018 Standout
Suppression of the SLC7A11/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma
2019
PROTAC targeted protein degraders: the past is prologue
2022 Standout
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2019 Standout
Targeting ferroptosis as a vulnerability in cancer
2022 Standout
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
2018 Standout
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy
2020 Standout
Using sulfuramidimidoyl fluorides that undergo sulfur(vi) fluoride exchange for inverse drug discovery
2020 StandoutNobel
ERK/MAPK signalling pathway and tumorigenesis (Review)
2020
Lipid Nanoparticles Delivering Constitutively Active STING mRNA to Stimulate Antitumor Immunity
2022 StandoutNobel
Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer
2015
The IL-4/IL-13 axis in skin fibrosis and scarring: mechanistic concepts and therapeutic targets
2019
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Ovarian cancer statistics, 2018
2018 Standout
Immune checkpoint inhibition in ovarian cancer
2016
Breast Cancer Treatment
2019 Standout
From Genetic Alterations to Tumor Microenvironment: The Ariadne’s String in Pancreatic Cancer
2020
In vitro evaluation of the inhibition and induction potential of olaparib, a potent poly(ADP-ribose) polymerase inhibitor, on cytochrome P450
2017
Cancer treatment and survivorship statistics, 2019
2019 Standout
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
2021 Standout
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Olaparib for Metastatic Castration-Resistant Prostate Cancer
2020
Angiogenic gene signature in human pancreatic cancer correlates with TGF-beta and inflammatory transcriptomes
2015
ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties
2021 Standout
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
2020
Immunology of Acute and Chronic Wound Healing
2021 Standout
Works of Karin Bowen being referenced
Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials
2018
Selumetinib in combination with docetaxel as second-line treatment for patients with KRAS-mutant advanced NSCLC: Results from the phase III SELECT-1 trial
2016
Phase I study of olaparib in combination with carboplatin and/or paclitaxel in patients with advanced solid tumors.
2013
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
2014 Standout
Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer
2017